These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 83018)

  • 41. Inhibition of functional and immunological responses to thyroid-stimulating antibodies from patients with Graves' disease by blockade of the thyrotropin receptor.
    Hoermann R; Schumm-Draeger PM; Mann K
    Thyroid; 1993; 3(4):273-8. PubMed ID: 7906974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differentiation of autoimmune ophthalmopathy from Graves' hyperthyroidism by analysis of genetic markers.
    Kendall-Taylor P; Stephenson A; Stratton A; Papiha SS; Perros P; Roberts DF
    Clin Endocrinol (Oxf); 1988 Jun; 28(6):601-10. PubMed ID: 3254259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T cell subsets and thyroid-stimulating antibodies in patients with Graves' disease in clinical remission.
    Bagnasco M; Macchia E; Ciprandi G; Caria M; Fenzi GF
    J Endocrinol Invest; 1986 Jun; 9(3):217-21. PubMed ID: 2876022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of c-fos and c-myc mRNA expression by immunoglobulin G from patients with Graves' disease in thyrotrophin-dependent rat thyroid cell line (FRTL5).
    Hatabu H; Kasagi K; Iida Y; Nosaka T; Misaki T; Hidaka A; Tokuda Y; Endo K; Mori T; Lee K
    Clin Endocrinol (Oxf); 1991 May; 34(5):349-56. PubMed ID: 1905596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal B lymphocyte function in thyroid glands from patients with Graves' disease.
    Ueki Y; Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Tezuka H; Nakao H; Kawakami A; Migita K; Ishikawa
    J Clin Endocrinol Metab; 1989 Nov; 69(5):939-45. PubMed ID: 2793996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced C4 in HLA-B8 positive patients with Graves' disease.
    Tom W; Farid NR
    Hum Hered; 1981; 31(4):227-31. PubMed ID: 6895210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA antigens in Greek patients with thyrotoxicosis (Graves' disease and toxic nodular goiter).
    Papasteriades C; Alevizaki-Harhalaki MN; Economidou J; Ikkos DG
    J Endocrinol Invest; 1984 Aug; 7(4):283-6. PubMed ID: 6594386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On the nature of the genes influencing the prevalence of Graves' disease.
    Adams DD; Adams YJ; Knight JG; McCall J; White P; Parkinson R; Horrocks R; van Loghem E
    Life Sci; 1983 Jan 3-10; 32(1-2):3-13. PubMed ID: 6687484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
    Moens H; Payne R; Carter ND; Farid NR
    Hum Hered; 1980; 30(1):62-4. PubMed ID: 6892568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell sensitization to autologous thyroid cells and normal non-specific suppressor T-cell function in Graves' disease.
    Davies TF; Bermas B; Platzer M; Roman SH
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):155-67. PubMed ID: 3157510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
    Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
    Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins.
    Auf'mkolk M; Ingbar JC; Kubota K; Amir SM; Ingbar SH
    Endocrinology; 1985 May; 116(5):1687-93. PubMed ID: 2985357
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simultaneous occurrence of subacute thyroiditis and Graves' disease.
    Hoang TD; Mai VQ; Clyde PW; Shakir MK
    Thyroid; 2011 Dec; 21(12):1397-400. PubMed ID: 22136271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of HLA types and clinical findings in Japanese patients with hyperthyroid Graves' disease: evidence indicating the existence of four subpopulations.
    Inoue D; Sato K; Enomoto T; Sugawa H; Maeda M; Inoko H; Tsuji K; Mori T; Imura H
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):75-82. PubMed ID: 1559302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyrotropin receptor non-mediated thyroid stimulating immunoglobulin in Graves' disease.
    Endo T; Haraguchi K; Ohmori M; Ikeda M; Ohta K; Onaya T
    Biochem Biophys Res Commun; 1991 Sep; 179(3):1543-7. PubMed ID: 1656957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Graves' IgG on gene transcription in human thyroid cell cultures. Thyroglobulin gene activation.
    Kung AW; Collison K; Banga JP; McGregor AM
    FEBS Lett; 1988 May; 232(1):12-6. PubMed ID: 2835260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenetic markers in patients with Graves' disease.
    Schifferdecker E; Kühnl P; Schöffling K; Manfras B; Holzberger G; Spielmann W; Böhm BO
    Klin Wochenschr; 1991 Apr; 69(6):256-60. PubMed ID: 2038175
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Connection between HLA-B8 antigen and suppressor T-cell activity in Graves' disease.
    Balázs C; Stenszky V; Kozma L; Szerze P; Leövey A
    Transplant Proc; 1979 Jun; 11(2):1314. PubMed ID: 314175
    [No Abstract]   [Full Text] [Related]  

  • 60. Association of HLA antigen BW35 with severe Graves' ophthalmopathy.
    Sergott RC; Felberg NT; Savino PJ; Blizzard JJ; Schatz NJ; Sanford CA
    Invest Ophthalmol Vis Sci; 1983 Jan; 24(1):124-7. PubMed ID: 6600737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.